KR20100062094A - A composition for preventing and treating allergy comprising the extract of ginseng berry, ginseng flower and ginseng stem - Google Patents

Abstract

PURPOSE: A composition using ginseng fruit, flower, and stem extract is provided to suppress histamine release and to ensure high anti-allergic effect. CONSTITUTION: A pharmaceutical composition for preventing and treating allergy contains ginseng fruit, flower, stem, and leaf extract as an active ingredient. The extract from ginseng contains 1-60 weight% of ginsenoside Re with activity of suppressing histamine release. The ginseng is Panax ginseng, Panax quinquefolium, Panax notoginseng, Panax japonicum, or Panax vietnamensis. The ginseng extract is obtained by heating for 0.5-24 hours with ethyl alcohol, butyl alcohol, or distilled water. The composition is used in the form of tablet, powder, pill, granule, capsule, suspension, emulsion, or syrup. A health food for preventing or treating allergy contains the ginseng extract as an active ingredient.

Description

A composition for preventing and treating allergy comprising the extract of ginseng berry, ginseng flower and ginseng stem}

The present invention relates to a composition for the treatment and prevention of allergy (allergy) containing a ginseng ( Panax ginseng ) fruit, ginseng, ginseng stem and ginseng leaf extract excellent anti-allergic effect.

In general, allergies are the body's hypersensitivity reactions to foreign substances (antigens) that are harmless to others, and the allergens that cause allergic reactions are called allergens, and typical allergens are pollen, drugs, vegetable fibers, threads, bacteria, foods, dyes Chemicals; Allergic reactions can be divided into immediate and delayed allergies, depending on whether the antigen reacts with B or T cells. Firstly, immediate allergic reactions are the result of antigen-antibody (product of B cell response) reactions, which are classified into three basic types.

First, type I allergic reactions are anaphylactic shock (anaphylaxis), and the individual predisposition is genetically determined and includes immunoglobulin E (IgE) antibodies that cause hay fever, insect allergens, and asthma. IgE is associated with mast cells found in dense connective tissue. When excess antigen binds to IgE antibodies, mast cells release histamine and heparin granules and produce substances such as leukotriene. These latent chemicals expand blood vessels and constrict the airways, the passages of air. In particular, histamine causes allergic runny nose, shortness of breath, and swelling of the skin.

The best way to prevent these allergies is to stop the influx of causative agents, and taking antihistamines can alleviate temporary pain. In addition, the prevention of desensitization is to inject the patient over a period of time while gradually increasing the antigen until the allergic reaction does not occur.

Second, type II allergic reactions are the result of the reaction of antigens and antibodies found in specific target cells, which may be innate components of healthy cells or foreign components such as drugs or infectious microorganisms. Antigen-antibody complexes activate the complement system, which consists of a series of latent enzymes that destroy target cells.

Third, type III allergic reactions occur when a person who is very sensitive to a particular antigen is continuously exposed to the antigen, in which the antigen-antibody complex is deposited on a small vessel wall. In this case, the complex stimulates complement and causes inflammation and vascular damage. Unlike the type I response, the type II and type III responses do not depend on genetic predisposition. Avoiding substances known as allergens is the best way to prevent this reaction.

On the other hand, the type IV response, which is a delayed allergic reaction, is caused by a T cell response and takes longer to accumulate at the site of the antigen than the B cell. The allergic reaction occurs 12 to 24 hours or more after exposure to the antigen, a typical delayed allergic reaction is contact dermatitis, and also because the rejection of the transplanted organ is also mediated by T cells, delaying It is also considered one of the allergic reactions.

Allergic diseases are representative chronic repetitive diseases, which are caused by the interaction of genetic and environmental factors. Types of allergic diseases include bronchial asthma, allergic rhinitis, allergic conjunctivitis, acute and chronic urticaria, atopic dermatitis, anaphylaxis. The three principles of allergy treatment are environmental management, drug therapy and immunotherapy.

First, the purpose of pharmacotherapy is to alleviate the symptoms of the patient, to prevent disease progression, to reduce morbidity and mortality, and to obtain the optimal therapeutic effect for each patient. Types of allergic drugs include antihistamines, beta agonists, theophylline, leukotriene antagonists, corticosteroids, and the first generation of antihistamines are traditional H1 antagonists, which act as competitive inhibitors to histamine at the receptor. Easily absorbed after oral administration, the action takes place within 15 to 30 minutes, peaks in 1 to 2 hours, and lasts for 3 to 6 hours and divides every 4 to 6 hours. Side effects include drowsiness, dizziness, helplessness, dry mouth, blurring, and nausea. The first generation of antihistamines include chlorpheniramine (Peniramin), hydroxyzine (Ucerax), and cyproheptadine (Prohechine).

On the other hand, second-generation antihistamines are non-competitively bound to H1 receptors, which do not fall easily by histamine, resulting in long action times, relatively high molecular weight, and static electricity, which limits the infiltration of the central nervous system, resulting in less sedation. In addition, the long half-life is taken once a day, side effects are less than the first generation, so use is recommended first. In recent years, depending on the drug, in addition to antihistamine action, mast cells and basophils inhibit the secretion of mediators or inhibit the secretion of mediators and thus are classified as antiallergic agents. Types of second-generation antihistamines include cetirizine (Lyratadine (Clarityne)), fexonadine (Allrgra), azelastine (Azeptin), Ebastine (Ebastel), and mizolastine. Mizolastine (Mizollen) and the like, among which topical antihistamines (Nasal spray) are azeptin and levocabastine (Livostin). In addition, indications include rhinitis, urticaria, atopy, dermatitis, asthma, etc. In addition, fexofenadine and cetirizine have been found to be stable in children. Most drugs are not stable. However, fexonadine and cetirizine are recommended if you have liver dysfunction.

In the case of allergic rhinitis, oral second-generation antihistamines and topical antihistamines are recommended as first-line drugs, and antihistamines have better relieving effects such as nausea, sneezing, and runny nose. Although less effective than oral mucosal constrictors such as pseudoephedrine, fexonadine (Allegra) and cetirizine (Zyrtec) have shown significant mucosal contraction effects in several studies. In addition, laratadine has a synergistic effect on anti-histamines such as loratadine and montelukast, as laratadine has a similar effect on nasal itching, sneezing, runny nose, and stuffy nose as leucotriene modulators such as montelukast. have. If more than the proper dose does not improve symptoms, only central nervous system side effects may increase, so you should consider changing to another antihistamine or using topical corticosteroids. Asthma Most antihistamines do not play a major role in the treatment of asthma and are therefore only useful for asthma patients with rhinitis.

In acute and chronic urticaria, antihistamines are the primary agents, and both first-generation and first- and second-generation combination therapy and second-generation combination therapy are available, among which H1 and H2 antihistamine combination therapy is effective. H2 blockers reduce vascular permeability and swelling size, and also act as CYP450 inhibitors. H1 blockers increase metabolism and target organ concentrations by inhibiting metabolism.

For atopic dermatitis, first-generation antihistamines such as hydroxyzine are recommended, and their sedation can relieve itching. In addition, the use of cetirizine (Zyrtec) and loratadine (Clarityne) in the second generation can improve the itch and reduce the amount of topical corticosteroids. The corticosteroids have a wide range of anti-inflammatory effects and are the most important agents prescribed systemically and topically. They are usually administered systemically in acute or severe asthma and allergic diseases, and in case of persistent asthma, allergic rhinitis or atopic dermatitis. Topical therapy (inhalants, nasal mucosa, skin ointments) should be administered in order to minimize the side effects of long-term use.

On the other hand, systemically administered steroids are non-aqueous and quick to absorb after oral administration. When used with antacids, the absorption rate is reduced by more than 50%. Compared to prednisolone, methylprednisolone has slow absorption and high permeability and latex to lung tissue, which is beneficial for asthma and other lung diseases. As the importance of airway inflammation in the pathophysiology of bronchial asthma has increased, the need for early use of anti-inflammatory drugs has been suggested. The use of inhaled corticosteroids with good local effect and less systemic effect has become more important.

Korean ginseng ( Panax ginseng ) is a product of Sin- Nong-Boncho , which is sweet and slightly warm, and is the representative specialty of Korea. Korean ginseng is a physiologically active substance and contains about 30 kinds of ginseng saponins, including ginsenoside Rb ₂ , which has antidiabetic action, polyacetylene, which has anticancer activity, a phenolic compound which has an antioxidant action, and a ginseng protein having a radiation defense action. And acidic polysaccharides having an immunomodulatory effect. In particular, Korean ginseng contains a large amount of phenolic compounds, polyacetylene and acidic polysaccharide components compared to Western ginseng ( Panax quinquefolium ), it is expected that stronger physiological activity. Ginseng saponin, known as the main pharmacological component of Korean ginseng, is called ginsenoside, and its chemical structure has been confirmed by Shibata group of Tokyo University. Thus, the ginseng saponins contained in Korean ginseng are about 30 species, which is much higher than 14 species of western ginseng and 15 kinds of Panax notoginseng . The ginsenosides are largely divided into a protopanaxadiol group and a protopanaxatriol group. The main components of the protopanaxadiol group, ginsenoside Rb ₁ , exhibit central nervous system suppression. Ginsenoside Rg ₁ , a major component of the ProtoPanaxatriol group, is known to exhibit central nervous system excitability and contribute to the adaptogen activity of Korean ginseng. In addition, ginsenoside Re is known to have a central neurosuppression action, DNA and RNA promoting action, prasmin activating action and adrenal cortical stimulating hormone secretion.

On the other hand, pharmacological experiments on the antiallergic activity of ginseng showed that in 2003, Choo et al., Compound K, a ginseng saponin enteromicrobial metabolite, inhibits beta hexosaminidase induced by RBL-2H3 cells and PCA reaction. [Cho et al., Planta medica 69 (6), 518, 2003]. In 2003, Park et al. Reported that ginsenoside Rh ₂ , a ginseng saponin enteromicrobial metabolite, was induced by RBL-2H3 cells and PCA reaction. Anti-allergic activity inhibiting beta hexosaminidase [Park et al., Bio. Pharm. Bull. 26 (11), 1581, 2003]. In 2004, Park et al. Reported that ginsenoside Rh ₁ , a ginseng saponin, acts as an antiallergic agent in PCA response to rat peritoneal mast cells [Park et al., Arch. Allergy Immunol. 133 (2), 113, 2004].

However, in the prior art, only the anti-allergic action of ginseng root extract was studied, but no research was conducted on the components extracted from ginseng fruit or ginseng. The present inventors found that not only ginseng root but also ginseng fruit or ginseng extract removed from ginseng contains a high concentration of ginsenoside Re, thus exhibiting significant antiallergic effect.

The present invention has a composition for the prevention and treatment of allergies containing ginseng fruit (pulp) or ginseng (lightning) extract as an active ingredient, which exhibits an antiallergic effect of free inhibition of histamine from human mast cells, and a pharmaceutical composition containing the same To provide a dietary supplement and cosmetic composition.

In order to achieve the above object, the present invention provides a pharmaceutical composition for allergy prevention and treatment containing an extract extracted from any one selected from the group consisting of ginseng fruit, ginseng, ginseng stem and ginseng leaves as an active ingredient.

In addition, the present invention provides a functional food for allergy prevention and improvement containing an extract extracted from any one selected from the group consisting of ginseng fruit, ginseng, ginseng stem and ginseng leaves as an active ingredient.

In addition, the present invention provides a cosmetic composition for allergy prevention and improvement containing an extract extracted from any one selected from the group consisting of ginseng fruit, ginseng, ginseng stem and ginseng leaves as an active ingredient.

The extract is added to the extract of any one selected from the group consisting of distilled water, ethyl alcohol and saturated butyl alcohol to any one selected from the group consisting of ginseng fruit, ginseng, ginseng stem and ginseng leaves 0.5 ~ 24 The extract may be obtained by heating and extracting at a temperature of 40 to 120 ° C. under reduced pressure, and the final extract according to the present invention may be in any form such as liquid or powder.

In addition, the extract extracted from any one selected from the group consisting of ginseng fruit, ginseng, ginseng stem and ginseng leaves may contain 1 to 60% of ginsenoside Re.

The ginseng fruit, ginseng, ginseng stem and ginseng leaves, such as Panax ginseng , Panax quinquefolium , Panax notoginseng , Panax japonicum or Panax vietnamensis Ground herbs of Panax genus plants, such as ginseng fruit (pulp), ginseng (flower bud), ginseng stems, ginseng leaves, and the processing of these, may also include repeated experiments involving ginseng It is based on the facts identified from. At this time, the processing may be extracted by a known method if necessary to make a processed ginseng extract. That is, the ginseng is extracted using water, lower alcohol (e.g. methanol, ethanol, etc.), lower ketone (e.g. acetone, methyl ethyl ketone, etc.), supercritical fluid or a mixed solvent thereof, and then concentrated or concentrated liquid. The dried ginseng extract, ie, ginseng, may be prepared in the form of softened or dried extract by drying the dried powdery processed ginseng extract.

In addition, it may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions according to the invention. Pharmaceutical dosage forms of the fractions of the invention may also be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination or mixed with other pharmaceutically active compounds.

In addition, the pharmaceutical compositions comprising the fractions according to the present invention may be prepared in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively. It can be formulated and used in the form. Carriers, excipients and diluents that may be included in the composition comprising the fractions include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations contain at least one excipient in the fraction, for example starch, calcium carbonate, sucrose. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

In addition, the preferred dosage of the pharmaceutical composition according to the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, the fraction of the present invention is preferably administered at 0.0001 to 100 mg / kg, especially at 0.001 to 100 mg / kg. Administration can be once or several times a day. The dosage does not limit the scope of the invention in any aspect.

In addition, the pharmaceutical composition according to the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.

In addition, the present invention is a health functional food comprising an extract and a food acceptable food supplement additive from any one selected from the group consisting of the ginseng fruit, ginseng, ginseng stem and ginseng leaves showing the prevention and treatment of allergies To provide. Examples of the food which can be added to the health functional food include various foods, beverages, gums, teas, vitamin complexes, and health functional foods. At this time, the amount of the composition in the food or beverage, in general, in the case of the health food composition of the present invention can be added to 0.0001 ~ 100% by weight, preferably 80% by weight or less of the total food weight, 100 ml in the health beverage composition It can be added in a ratio of 0.0001 to 10 g, preferably 5.0 g or less on the basis of.

The health beverage composition does not have any particular limitation on the liquid component except for containing the fraction as an essential component in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional components, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tautin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, colorants and enhancers (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is generally selected in the range of 0 to 20 parts by weight per 100 parts by weight of the composition of the present invention.

According to the present invention by the above-mentioned means for solving the problem, the ginseng fruit and ginseng, ginseng stem and ginseng leaf extract of the present invention exhibits histamine free inhibitory activity from mast cells, and has an excellent antiallergic effect, preventing and treating allergy. It can be usefully used as a pharmaceutical composition, health functional food and cosmetic composition.

Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are merely to illustrate the present invention, but the content of the present invention is not limited by the following examples.

Example

Example 1: Isolation of Ginseng Extract

Ginseng fruit Jeonbuk Wanju and Ginseng were obtained from Geumsan Ginseng Distribution Market and Ginseng Stem and Leaf from Jecheon Herbal Medicine Distribution Market.

<1-1> ginseng fruit

100 g of ginseng fruit was added to 10 times of 95% ethyl alcohol and extracted with reflux cooling twice at 80 ° C. for 2 hours, followed by freeze drying after concentration under reduced pressure to obtain a reddish brown extract.

<1-2> ginseng fruit

The 95% ethyl alcohol extract obtained in Example <1-1> was suspended in distilled water, extracted 10 times with saturated butyl alcohol, and extracted three times in a separatory funnel. The butyl alcohol layer was fractionated, concentrated under reduced pressure, and freeze-dried to reddish brown. An extract of was obtained.

<1-3> ginseng fruit

100 g of ginseng fruit was added to 10-fold distilled water, extracted with reflux cooling for 2 hours at 80 ° C., concentrated under reduced pressure, and lyophilized to give a reddish brown extract.

<1-4> ginseng flower

100 g of ginseng was added to 10 times of 95% ethyl alcohol and extracted with two reflux cooling at 80 ° C. for 2 hours, and then concentrated under reduced pressure and lyophilized to obtain a reddish brown extract.

<1-5> ginseng stem

100 g of ginseng stem was added to 10 times of 95% ethyl alcohol and extracted with two reflux cooling at 80 ° C. for 2 hours, followed by freeze drying after concentration under reduced pressure to obtain a reddish brown extract.

<1-6> ginseng leaf

100 g of ginseng leaves were extracted into 10% of 95% ethyl alcohol, extracted by refluxing twice at 80 ° C. for 2 hours, and then concentrated under reduced pressure and lyophilized to obtain a reddish brown extract.

Comparative Example 1: Isolation of Ginseng Extract

100 g of four-year-old ginseng (Ginseng) lyophilisate purchased from Geumsan Ginseng Center was added to 10-fold 95% ethyl alcohol, extracted by refluxing twice at 80 ° C for 2 hours, and concentrated under reduced pressure. Obtained.

Example 2: Isolation Identification of Ginsenoside Re

The 95% ethyl alcohol extract obtained in Example <1-1> was suspended in distilled water and adsorbed onto a Diion column, and then the fraction obtained by developing with 30% ethyl alcohol was concentrated under reduced pressure. In addition, the obtained fractions were loaded on a Sephadex LH-20 column and developed with 30% ethyl alcohol, and the obtained fractions were concentrated under reduced pressure, and the obtained fractions were loaded on an ODS column and developed with 30% ethyl alcohol. White powder compound I represented by formula (1) was obtained. As shown in FIGS. 3, 4 and 5, the obtained compound I was identified as ginsenoside Re by identifying the chemical structure by spectroscopic methods of NMR and MS.

 In Formula 1, Rha represents α-L-rhamnopyranosyl, and Glc represents β-D-glucopyranosyl.

Carbon NMR Data of Compound I Carbon no. G-Re Compound Ⅰ C-1 39.43 38.24 C-2 27.50 26.34 C-3 78.35 77.19 C-4 39.77 38.58 C-5 61.52 61.43 C-6 74.33 73.17 C-7 45.75 44.53 C-8 40.96 39.78 C-9 49.32 48.14 C-10 39.17 37.98 C-11 60.60 59.41 C-12 70.04 68.77 C-13 48.80 47.66 C-14 51.20 50.00 C-15 30.61 29.33 C-16 26.42 25.22 C-17 51.52 50.27 C-18 17.32 16.10 C-19 17.46 16.22 C-20 83.08 81.85 C-21 22.15 20.90 C-22 35.77 34.61 C-23 23.26 21.82 C-24 125.75 124.56 C-25 130.74 129.49 C-26 25.60 24.35 C-27 17.59 16.35 C-28 31.99 29.53 C-29 17.06 15.87 C-30 17.00 15.81 20-Glc 1 98.06 96.86 20-Glc 2 74.95 73.75 20-Glc 3 78.94 77.80 20-Glc 4 71.28 70.19 20-Glc 5 78.20 76.98 20-Glc 6 62.55 61.43  6-Glc 1 101.63 100.442  6-Glc 2 79.18 77.99  6-Glc 3 78.13 76.90  6-Glc 4 72.05 70.87  6-Glc 5 78.06 76.83  6-Glc 6 62.82 61.66   -Rha 1 101.69 100.441   -Rha 2 72.32 71.16   -Rha 3 72.21 71.01   -Rha 4 73.91 72.75   -Rha 5 69.26 68.06   -Rha 6 18.55 17.34

Example 3: Ginsenoside and Ginsenoside Re Component Analysis by HPLC Method

50 g of each sample was treated three times with ether, and then the aqueous part was treated three times with saturated butyl alcohol, and the butyl alcohol layer was concentrated under reduced pressure to obtain crude saponin (Sibata method). . The obtained crude saponin was quantified by HPLC method, the results are shown in Table 2 below. In HPLC analysis, each ginseng saponin component prepared a calibration curve based on 1 mg / ml (1000 ppm), and each sample was prepared by injecting 10 mg / ml (10000 ppm). At this time, HPLC conditions are as follows:

HPLC: Waters 1525 binary HPLC system (Waters, USA)

Column: Gemini 5μ C ₁₈ 110A (Phenomenex, 4.6 × 50mm, USA)

Detector: UV / VIS Waters 2487 Dual Absorbance Detector (Waters, U.S.A.)

Temperature: room temperature

Mobile phase: (CH ₃ CN , 17% → 40% → 60% → 80% → 17%)

Ginsenoside Composition (%, w / w) Example <1-1> Example <1-2> Example <1-3> Example <1-4> Example <1-5> Example <1-6> Comparative Example 1 Rb ₁ 0.621 ± 0.162 1.674 ± 0.437 0.312 ± 0.148 0.716 ± 0.018 0.1302 ± 0.009 0.1515 ± 0.014 0.596 ± 0.016 Rb ₂ 0.721 ± 0.027 2.481 ± 0.092 0.351 ± 0.103 0.636 ± 0.030 0.0201 ± 0.001 0.0257 ± 0.002 0.203 ± 0.001 Rc 0 0 0 0.003 ± 0.002 0.0331 ± 0.002 0.0276 ± 0.021 0.409 ± 0.010 Rd 0.472 ± 0.042 2.764 ± 0.243 0.232 ± 0.092 0.736 ± 0.050 0.0712 ± 0.006 0.0933 ± 0.001 0.101 ± 0.001 Re 5.989 ± 0.088 40.191 ± 0.594 1.521 ± 0.043 3.388 ± 0.125 0.682 ± 0.174 0.746 ± 0.070 0.213 ± 0.010 Rf 0 0 0 0.028 ± 0.002 0.0296 ± 0.004 0.0360 ± 0.004 0.052 ± 0.002 Rg ₁ 0.473 ± 0.005 3.088 ± 0.034 0.211 ± 0.012 0.585 ± 0.020 0.2861 ± 0.071 0.3966 ± 0.051 0.291 ± 0.014 Rg ₂ 0.704 ± 0.041 2.589 ± 0.150 0.364 ± 0.038 0.732 ± 0.038 0.0316 ± 0.002 0.0358 ± 0.005 0 Rh ₁ 0.111 ± 0.009 1.258 ± 0.102 0.509 ± 0.011 0.032 ± 0.002 0.0249 ± 0.000 0.0252 ± 0.007 0 Total Ginsenosides ^a) 9.09 54.05 3.50 6.86 1.31 1.54 1.87 Re / (Total Ginsenosides) ^b) 66 & 74% 44% 49% 52% 48% 11%

^a) Rb1 + Rb2 + Rc + Rd + Re + Rf + Rg1

^b) [Re / (Rb1 + Rb2 + Rc + Rd + Re + Rf + Rg1)] × 100

The numerical values in the table are expressed as mean ± SE (n = 3).

Table 2 shows the results of analyzing the content of each ginsenoside in the crude saponin obtained by the Shibata method for the ginseng fruit and ginseng extract according to the present invention. While ginsenoside Re is included as 11% of the ginsenoside in ginseng extract, the ginseng fruit and ginseng composition according to the present invention contained 44 to 74%. In particular, in the composition of Example <1-2>, the content of ginsenoside Re was 40.191%, showing a high content ratio of 74% relative to the total ginsenoside, and also in the case of the composition of Example <1-1>. The content of ginsenoside Re was 5.989%, indicating a high content ratio of 66% relative to the total ginsenosides. However, in the ginseng root composition of Comparative Example 1, the content of ginsenoside Re was 0.213%, indicating a low content ratio of 11% relative to the total ginsenoside.

Example 4: Compound 48/80 Induced Histamine Secretion Test

10% bovine serum albumin, 2 mM L-glutamine, 100 IU / ml penicillin, 50 ug / ml streptomycin was added to the human mast cell line (HMC), a mast cell line cultured from Iscove's Modified Dulbecco's Media (IMDM). Cells were treated with 37% 5% CO ₂ Incubated at 95% humidity for 2-3 days.

HMC was stabilized for 24 hours in 24 well plates and then incubated with each sample for 3 hours. Subsequently, compound 48/80 (Sigma-Aldrich Chemical. Co., St Louis, Mo.) was treated to induce histamine secretion. After 10 minutes, 100ul of each sample was taken, and 50ul of 1M NaOH and 100ul of 1 mg / ml OPA (o-phthaldialdehyde) EtOH aqueous solution were added thereto to react for 5 minutes, and the reaction was stopped with sulfuric acid solution. Fluorescence stimulation wavelength (excitation) 360/40, fluorescence emission wavelength (emission) 460/40 fluorescence wavelength was used and quantified by comparing with the histamine standard curve.

Example 5: Statistical Processing

All experimental results are expressed as mean ± standard deviation (mean ± SE). Statistical treatment was tested by Student's t-test, and it was judged that there was a significant difference in the case of high fat diet below P <0.05 compared with the control group.

Example 6 Histamine Secretion Inhibitory Effect

In Example 4, the anti-allergic effect of the sample was confirmed by observing the antihistamine effect of the sample using HMC. Compound 48/80 was used to induce histamine secretion, and the samples of Examples <1-1>, <1-4>, <1-5>, and <1-6> were administered at different concentrations.

As shown in Table 3, the results of the experiment of Example <1-1> showed that the control group had a histamine secretion of 3.00 ± 0.20 compared to the histamine secretion (19.9 ± 3.11) of the group treated with Compound 48/80.

In addition, the experimental groups (100, 30, 10, 3 and 1 (ug / ml)) treated with Example <1-1> were 13.7 ± 3.67, 6.63 ± 0.68, 11.1 ± 1.74, 15.2 ± 1.39 and 13.6, respectively, by concentration. The histamine secretion amount was ± 0.28, and significant histamine release inhibitory effects were observed at doses of 30 and 10 ug / ml (see FIG. 1).

In addition, the experimental group treated with Example <1-4> (300, 100 and 10 (ug / ml)) showed histamine secretion of 14.4 ± 0.66, 15.7 ± 2.15 and 14.0 ± 4.42 by concentration, respectively, 300, 100 And a significant histamine release inhibitory effect at a dose of 10 ug / ml.

In addition, the experimental group (300, 100 and 10 (ug / ml)) treated with Example <1-5> showed histamine secretions of 16.3 ± 1.63, 16.1 ± 1.67 and 15.0 ± 1.12, respectively, by concentration, and 300, 100 And a significant histamine release inhibitory effect at a dose of 10 ug / ml.

In addition, the experimental group treated with Example <1-6> (300, 100 and 10 (ug / ml)) showed histamine secretion of 17.9 ± 1.38, 16.1 ± 1.37 and 15.2 ± 0.38 by concentration, respectively, 300, 100 And a significant histamine release inhibitory effect at a dose of 10 ug / ml.

In addition, the experimental group treated with Compound I (100, 30, 10, 3 and 1 (ug / ml)) of the histamine secretion of 19.7 ± 0.76, 0.54 ± 0.20, 11.2 ± 0.77, 11.9 ± 0.90 and 11.5 ± 0.80, respectively, by concentration And dose-dependent histamine free inhibitory effects at doses of 30, 10, 3 and 1 ug / ml (see FIG. 2).

Inhibitory Effect of Compound Ginseng Fruit, Flower, Stem and Leaf on Compound 48 / 80-induced Histamine Release sample Concentration (ug / ml) Histamine amount (ug / ml) normal 0 3.00 ± 0.20 Control 0 19.9 ± 3.11 Example <1-1> 100 13.7 ± 3.67  30 6.63 ± 0.68 ^**  10 11.1 ± 1.74 ^*   3 15.2 ± 1.39   One 13.6 ± 0.28 Example <1-4> 300 14.4 ± 0.66 ^* 100 15.7 ± 2.15 ^* 10 14.0 ± 4.42 ^* Example <1-5> 300 16.3 ± 1.63 ^* 100 16.1 ± 1.67 ^* 10 15.0 ± 1.12 ^* Example <1-6> 300 17.9 ± 1.38 ^* 100 16.1 ± 1.37 ^* 10 15.2 ± 0.38 ^* Compound I (Ginsenoside Re) 100 19.7 ± 0.76  30 0.54 ± 0.20 ^**  10 11.2 ± 0.77 ^*   3 11.9 ± 0.90 ^*   One 11.5 ± 0.80 ^*

**: P <0.01 for control, *: P <0.05 for control

Mean ± standard deviation (mean ± SE) (n = 3) described in Table 3 above.

As a result of the experiment, the extract according to the present invention contained a large amount of the compound I ginsenoside Re, it was confirmed that the anti-allergic effect is excellent by showing histamine free inhibitory activity.

Formulation Example 1 Preparation of Injection

Dry powder of the extract of Example <1-1> ............... 100 mg

pH Adjuster ... ..... suitable

The above ingredients were mixed and prepared in a conventional manner, and then injected into a 2 ml ampoule and sterilized to prepare an injection.

Formulation Example 2: Preparation of Tablet

Dry powder of the extract of Example <1-1> ............... 50 mg

Lactose ... ....... 125 mg

Microcrystalline cellulose ... 75 mg

Magnesium Stearate .........................................

The tablets were prepared by mixing the above components and tableting according to a conventional method for producing tablets.

Formulation Example 3 Preparation of Capsule

Dry powder of the extract of Example <1-1> ........................ 100 mg

Lactose ... ....... 125 mg

Starch ..................... ....... 125 mg

Talc .................. ....... suitable

Magnesium Stearate ...............

The capsules are prepared by mixing the above ingredients and filling the capsules according to a conventional method for preparing capsules.

Formulation Example 4 Preparation of Liquid

Dry powder of the extract of Example <1-1> ........ 1000 mg

Per minute................................................. ......... 20 g

Isomerized sugar ... ...... 20 g

Lemon flavor ....... suitable

Purified water is added to adjust the total volume to 1000 ml. According to the conventional method for preparing a liquid, the above components were mixed to prepare a liquid.

Formulation Example 5 Preparation of Health Food

Dry powder of the extract of Example <1-1> ....................... 100 mg

Vitamin A Acetate ......................... 70 μg

Vitamin E ...................................... ... 1.0 mg

Vitamin B1 ... .0.13 mg

Vitamin B2 ..................... .0.15 mg

Vitamin B6 ... ..0.5 mg

Vitamin B12 ... .0.2 mg

Vitamin C ... .... 10 mg

Biotin ... ..... 10 ㎍

Nicotinic Acid Amide ... 1.7 mg

Folic Acid ... ....... 50 μg

Calcium Pantothenate ......................................... 0.5 mg

Ferrous Sulfate ............. ... 1.75 mg

Zinc Oxide ... ..0.82 mg

Magnesium Carbonate ......................................... 25.3 mg

Although the formulation of the preparation example 1, the vitamin, and the mineral mixture of the above-mentioned preparations are prepared by mixing the ingredients suitable for health foods in a preferable composition ratio according to a conventional method, the compounding ratio may be arbitrarily modified.

Formulation Example 6 Preparation of Healthy Drinks

Dry powder of the extract of Example <1-1> .................... 1000 mg

Citric Acid ... ... 1000 mg

oligosaccharide................................................. ... 20 mg

Taurine ... .... 100 mg

Purified water was added to adjust the total amount to 900 ml, and prepared according to the conventional healthy beverage preparation method.

In the above formulation example, the components suitable for the favorite beverages were mixed at a preferable composition ratio which is usually applied, and therefore, the blending ratio may be arbitrarily modified.

1 is a result of comparing the histamine glass change pattern of the composition used in Example 1.

Figure 2 is a result of comparing the histamine glass change pattern of the composition used in Example 2.

3 is the H ¹ -NMR result of compound I.

4 is a C ¹³ -NMR result of Compound I. FIG.

5 is a result of fast atom bombardment mass spectrometry (FAB-MS) of compound I.

Claims (13)

A pharmaceutical composition for preventing and treating allergies containing an extract extracted from any one selected from the group consisting of ginseng fruit, ginseng flower, ginseng stem and ginseng leaf as an active ingredient. According to claim 1, wherein the extract is allergic prevention and treatment pharmaceutical composition, characterized in that containing 1 to 60% by weight of ginsenoside Re having a histamine free inhibitory activity. The pharmaceutical composition of claim 1, wherein the extract is prepared by heating and extracting for 0.5 to 24 hours with any one solvent selected from the group consisting of ethyl alcohol, butyl alcohol and distilled water. According to claim 1, The ginseng is any one selected from the group consisting of Panax ginseng , Panax quinquefolium , Panax notoginseng , Panax japonicum and Panax vietnamensis Pharmaceutical composition for preventing and treating allergy, characterized in that. The composition of claim 1, wherein the composition is formulated in the form of tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions or syrups, external preparations, suppositories or sterile injectable solutions. Allergy prevention and treatment pharmaceutical composition. Allergy prevention and improvement health functional food containing the extract extracted from any one selected from the group consisting of ginseng fruit, ginseng flower, ginseng stem and ginseng leaf as an active ingredient. According to claim 6, wherein the extract is allergic prevention and improvement health functional food containing ginsenoside Re having a histamine free inhibitory activity in 1 to 60% by weight. According to claim 6, The extract is allergic prevention and improvement health functional food, characterized in that is produced by heating extraction for 0.5 to 24 hours with any one solvent selected from the group consisting of ethyl alcohol, butyl alcohol and distilled water. The ginseng is any one selected from the group consisting of Panax ginseng , Panax quinquefolium , Panax notoginseng , Panax japonicum and Panax vietnamensis . Allergy prevention and improvement health functional food characterized in that the. Allergy prevention and improvement cosmetic composition containing an extract extracted from any one selected from the group consisting of ginseng fruit, ginseng, ginseng stem and ginseng leaf as an active ingredient. The cosmetic composition for allergy prevention and improvement of claim 10, wherein the extract contains 1 to 60% by weight of ginsenoside Re having histamine free inhibitory activity. The cosmetic composition for preventing and improving allergy according to claim 10, wherein the extract is prepared by heat extraction for 0.5 to 24 hours with any one solvent selected from the group consisting of ethyl alcohol, butyl alcohol and distilled water. The method of claim 10, wherein the ginseng is any one selected from the group consisting of Panax ginseng , Panax quinquefolium , Panax notoginseng , Panax japonicum and Panax vietnamensis . Allergy prevention and improvement cosmetic composition characterized in that.

Images